|
1
|
Lu J, He ML, Wang L, Chen Y, Liu X, Dong
Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP: MiR-26a inhibits
cell growth and tumorigenesis of nasopharyngeal carcinoma through
repression of EZH2. Cancer Res. 71:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang GL, Lu Y, Pu XX, He YX, Chen ML, Li
YZ, Tang SY, Che H and He Z: Association study between miR-149 gene
polymorphism and nasopharyngeal carcinoma. Biomed Rep. 1:599–603.
2013.
|
|
3
|
McDermott AL, Dutt SN and Watkinson JC:
The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied
Sci. 26:82–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu N, Jiang N, Guo R, Jiang W, He QM, Xu
YF, Li YQ, Tang LL, Mao YP, Sun Y and Ma J: MiR-451 inhibits cell
growth and invasion by targeting MIF and is associated with
survival in nasopharyngeal carcinoma. Mol Cancer. 12:1232013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu
LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma
patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011.
View Article : Google Scholar
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho HJ, Liu G, Jin SM, Parisiadou L, Xie
C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, et al:
MicroRNA-205 regulates the expression of Parkinson's
disease-related leucine-rich repeat kinase 2 protein. Hum Mol
Genet. 22:608–620. 2013. View Article : Google Scholar :
|
|
8
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu Y, Huang Z and Liu Y: Reduced
miR-125a-5p expression is associated with gastric carcinogenesis
through the targeting of E2F3. Mol Med Rep. 10:2601–2608.
2014.PubMed/NCBI
|
|
11
|
Zhou JJ, Zheng S, Sun LF and Zheng L:
MicroRNA regulation network in colorectal cancer metastasis. World
J Biol Chem. 5:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
You J, Li Y, Fang N, Liu B, Zu L, Chang R,
Li X and Zhou Q: MiR-132 suppresses the migration and invasion of
lung cancer cells via targeting the EMT regulator ZEB2. PLoS One.
9:e918272014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Li X, Kong X, Luo Q, Zhang J and
Fang L: MiRNA-26b inhibits cellular proliferation by targeting CDK8
in breast cancer. Int J Clin Exp Med. 7:558–565. 2014.PubMed/NCBI
|
|
15
|
Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z,
Zhang S, Nie L and Yu Z: MiR-145 functions as tumor suppressor and
targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J
Cancer Res Clin Oncol. 140:387–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu
K, Wei L and Chu M: The prognostic value of miR-21 and miR-155 in
non-small-cell lung cancer: A meta-analysis. Jpn J Clin Oncol.
43:813–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ and
Li GX: MicroRNA-338-3p inhibits colorectal carcinoma cell invasion
and migration by targeting smoothened. Jpn J Clin Oncol. 44:13–21.
2014. View Article : Google Scholar
|
|
18
|
Huang GL, Lu Y, Pu XX, He YX, Chen ML, Li
YZ, Tang SY, Che H and He Z: Association study between miR-149 gene
polymorphism and nasopharyngeal carcinoma. Biomed Rep. 1:599–603.
2013.
|
|
19
|
Huang GL, Chen ML, Li YZ, Lu Y, Pu XX, He
YX, Tang SY, Che H, Zou Y, Ding C and He Z: Association of miR-146a
gene polymorphism with risk of nasopharyngeal carcinoma in the
central-southern Chinese population. J Hum Genet. 59:141–144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu X, Wang Y, Sun Y, Zheng J and Zhu D:
MiR-155 up-regulation by LMP1 DNA contributes to increased
nasopharyngeal carcinoma cell proliferation and migration. Eur Arch
Otorhinolaryngol. 271:1939–1945. 2014. View Article : Google Scholar
|
|
21
|
Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang
L, Li J, Peng H, Cho WC, Wang E, et al: TGFβR2 is a major target of
miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer.
13:512014. View Article : Google Scholar
|
|
22
|
Liu Y, Li Z, Wu L, Wang Z, Wang X, Yu Y,
Zhao Q and Luo F: MiRNA-125a-5p: A regulator and predictor of
gefitinib's effect on nasopharyngeal carcinoma. Cancer Cell Int.
14:242014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Liao H, Deng Z, Yang P, Du N,
Zhanng Y and Ren H: MiRNA-205 affects infiltration and metastasis
of breast cancer. Biochem Biophys Res Commun. 441:139–143. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalogirou C, Spahn M, Krebs M, Joniau S,
Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H and Kneitz B:
MiR-205 is progressively down-regulated in lymph node metastasis
but fails as a prognostic biomarker in high-risk prostate cancer.
Int J Mol Sci. 14:21414–21434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tian L, Zhang J, Ge J, Xiao H, Lu J, Fu S,
Liu M and Sun Y: MicroRNA-205 suppresses proliferation and promotes
apoptosis in laryngeal squamous cell carcinoma. Med Oncol.
31:7852014. View Article : Google Scholar
|
|
26
|
Su N, Qiu H, Chen Y, Yang T, Yan Q and Wan
X: MiR-205 promotes tumor proliferation and invasion through
targeting ESRRG in endometrial carcinoma. Oncol Rep. 29:2297–2302.
2013.PubMed/NCBI
|
|
27
|
Gottardo F, Liu CG, Ferracin M, Calin GA,
Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et
al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cui M, Xiao Z, Sun B, Wang Y, Zheng M, Ye
L and Zhang X: Involvement of cholesterol in hepatitis B virus X
protein-induced abnormal lipid metabolism of hepatoma cells via
up-regulating miR-205-targeted ACSL4. Biochem Biophys Res Commun.
445:651–655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun Y, Mao YP, Ma J, Huang Y, Tang LL,
Wang Y, Liu LZ and Lu TX: Influences of magnetic resonance imaging
on the staging system of nasopharyngeal carcinoma. Ai Zheng.
26:158–163. 2007.PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Liu Y, Yang K, Sun X, Fang P, Shi H, Xu J,
Xie M and Li M: MiR-138 suppresses airway smooth muscle cell
proliferation through the PI3K/AKT signaling pathway by targeting
PDK1. Exp Lung Res. Jul 7–2015.Epub ahead of print. View Article : Google Scholar
|
|
32
|
Li R, Shi X, Ling F, Wang C, Liu J, Wang W
and Li M: MiR-34a suppresses ovarian cancer proliferation and
motility by targeting AXL. Tumor Biol. Apr 21–2015.Epub ahead of
print.
|
|
33
|
Chen JJ, Liu SX, Chen MZ and Zhao ZY:
Has-miR-125a and 125b are induced by treatment with cisplatin in
nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent
manner by targeting p53 mRNA. Mol Med Rep. 12:3569–3594.
2015.PubMed/NCBI
|
|
34
|
Luo Z, Zhang L, Li Z, Li X and Li G, Yu H,
Jiang C, Dai Y, Guo X, Xiang J and Li G: An in silico analysis of
dynamic changes in microRNA expression profiles in stepwise
development of nasopharyngeal carcinoma. BMC Med Genomics. 5:32012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qu C, Liang Z, Huang J, Zhao R, Su C, Wang
S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the
radioresistance of human nasopharyngeal carcinoma by directly
targeting PTEN. Cell cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tomasini R, Samir AA, Pebusque MJ, Calvo
EL, Totaro S, Dagorn JC, Dusetti NJ and Iovanna JL: P53-dependent
expression of the stress-induced protein (SIP). Eur J Cell Biol.
81:294–301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okamura S, Arakawa H, Tanaka T, Nakanishi
H, Ng CC, Taya Y, Monden M and Nakamura Y: p53DINP1, a
p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell.
8:85–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tomasini R, Samir AA, Carrier A, Isnardon
D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL and
Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2
(HIPK2) are partners in regulating p53 activity. J Biol Chem.
278:37722–37729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
D'Orazi G, Cecchinelli B, Bruno T, Manni
I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal
G, et al: Homeodomain-interacting protein kinase-2 phosphorylates
p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 4:11–19. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang PH, Motoo Y, Garcia S, Iovanna JL,
Pébusque MJ and Sawabu N: Down-expression of tumor protein
p53-induced nuclear protein 1 in human gastric cancer. World J
Gastroenterol. 12:691–696. 2006.PubMed/NCBI
|
|
41
|
Zhang J, Cheng C, Yuan X, He JT, Pan QH
and Sun FY: microRNA-155 acts as an oncogene by targeting the tumor
protein 53-induced nuclear protein 1 in esophageal squamous cell
carcinoma. Int J Clin Exp Pathol. 7:602–610. 2014.PubMed/NCBI
|
|
42
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei Q, Li YX, Liu M, Li X and Tang H:
MiR-17-5p targets TP53INP1 and regulates cell proliferation and
apoptosis of cervical cancer cells. IUBMB Life. 64:697–704. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shahbazi J, Lock R and Liu T: Tumor
protein 53-induced nuclear protein 1 enhances p53 function and
represses tumorigenesis. Front Genet. 4:802013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Giusiano S, Baylot V, Andrieu C, Fazli L,
Gleave M, Iovanna JL, Taranger-Charpin C, Garcia S and Rocchi P:
TP53INP1 as new therapeutic target in castration-resistant prostate
cancer. Prostate. 72:1286–1294. 2012. View Article : Google Scholar : PubMed/NCBI
|
